OTC Markets OTCQB - Delayed Quote ? USD Panbela Therapeutics, Inc. (PBLA) Follow Compare 0.3488 +0.0281 (+8.76%) At close: 3:07 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Panbela Provides Business Update and Reports Q3 2024 Financial Results MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic i GlobeNewswire ? 8 days ago PBLA +8.76% Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024 MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494We GlobeNewswire ? 22 days ago PBLA +8.76% First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combinat GlobeNewswire ? last month PBLA +8.76% Panbela Provides Business Update and Reports Q2 2024 Financial Results MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third indepe GlobeNewswire ? 3 months ago PBLA +8.76% Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024 MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Li GlobeNewswire ? 3 months ago PBLA +8.76% Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therape GlobeNewswire ? 4 months ago PBLA +8.76% Panbela Announces Oral Presentation at Digestive Disease Week (DDW): Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin AmericanMINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21, GlobeNewswire ? 5 months ago PBLA +8.76% Panbela Provides Business Update and Reports Q1 2024 Financial Results MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. Q1 2024 and recent Highlights: Clinical Announced revised timing for the interim data analysis for its o GlobeNewswire ? 6 months ago PBLA +8.76% Panbela Announces Issuance of New Patent in the US and Canada;?Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac Developed in collaboration with Sanofi.MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combi GlobeNewswire ? 6 months ago PBLA +8.76% Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024 MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Lin GlobeNewswire ? 6 months ago PBLA +8.76% Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company’s on-going collaboration with Vanderbilt Univ GlobeNewswire ? 6 months ago PBLA +8.76% Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025 Trial's lower-than-expected event rate suggests improved survival outcomesMINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025. This delay in the projected date for analysis comes as a result of the t GlobeNewswire ? 6 months ago PBLA +8.76% Panbela Announces Poster Presentation at American Association for Cancer Research: Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer modelsMINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Associ GlobeNewswire ? 7 months ago PBLA +8.76% Panbela Announces Transfer to OTCQB Market MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela’s common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.” OTCQB is a venture market operated by the OTC Markets Group Inc GlobeNewswire ? 7 months ago PBLA +8.76% Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2023 and early 2024 Highlights: Collaborations Divestiture of Assets within Eflornith GlobeNewswire ? 7 months ago PBLA +8.76% Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024 MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: GlobeNewswire ? 8 months ago PBLA +8.76% Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February GlobeNewswire ? 9 months ago PBLA +8.76% Panbela Announces Closing of Approximately $9.0 Million Public Offering MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Public Warrants”) at a GlobeNewswire ? 9 months ago PBLA +8.76% Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR) MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been accepted for poster presentation at the American Association for Cancer Research (AACR), which will be held April 5-10, 2024. The work reflects the Company’s on-going collaboration with Johns Hopkins U GlobeNewswire ? 9 months ago PBLA +8.76% Panbela Announces Pricing of Approximately $9.0 Million Public Offering MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 4,375,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) two classes of warrants to purchase up to an aggregate of 8,750,000 shares of its common stock (the “Common Warrants”) at a purchase price of $2.0 GlobeNewswire ? 9 months ago PBLA +8.76% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return PBLA S&P 500 YTD -98.09% +25.15% 1-Year -96.56% +31.54% 3-Year -100.00% +27.06%
